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Abstract: Determining the spatial configuration of the structures of compounds used in the production of medicines is 
extremely important due to the different characteristics of each of them in its solid state and therefore its different 
qualities of each for use as pharmaceutical raw material. This study aimed to identify the phase of the solid state of 
Atorvastatin hemi-dihydrate, a lipid-lowering medication HMG-CoA reductase widely use in the present and their 
characterization by four different instrumental analytical techniques: X-ray diffractometry, differential scanning 
calorimetry, thermogravimetry and infrared spectroscopy, comparing the obtained analytical results with those found in 
the literature. Using data obtained from these four techniques are able to show that the study sample exists predominantly 
in the 27 form of amorphic hemi-dihydrate calcic atorvastatin. 
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INTRODUCTION 
Polymorphism is defined as the ability of a 
substance to exist in various crystalline forms with a 
different spatial arrangement of the molecules in the 
crystal, these compositions have different spatial forms 
with different physicochemical characteristics in the 
solid state and different dissolution and absorption 
behaviors. Another possibility is the existence of an 
amorphous state, which is characterized by a disordered 
conformation of the molecules, these compounds have 
advantages and disadvantages with respects to the 
polymorphic states, as it favored the dissolution process 
also an amorphic state are typically unstable, have an 
increased hygroscopicity and tend to crystallize[1, 2]. 
 
Some of the pharmaceutical characteristics that 
can be affected are the melting point, hygroscopicity, 
physicochemical stability, apparent solubility and 
dissolution and hence its bioavailability. It is possible 
that the conformation of these compounds varies from 
one to another crystalline or amorphous state as result 
of normal processes in the manufacture and distribution 
of drugs such as mixing, micronization, wet 
granulation, transport and light compression, among 
others. Because of all these, is very important to be 
clear which polymorph or amorphous structure is 
available at the time of manufacture solid dosage forms 
and that because the effect of the manufacturing process 
there’s nochange in the solid state[2, 3]. 
 
The aim of this work is to determine the 
possible existence of polymorphic forms, amorphous or 
even pseupolimorphism in raw material used in the 
production of medicines and to characterize it by the 
complementary use of four instrumental techniques: X-
ray diffraction, calorimetry differential scanning 
calorimetry, thermogravimetry and infrared 
spectroscopy and compare it with other studies found in 
the literature. Atorvastatin was used as the test 
substance which was provided by the Costa Rican 
pharmaceutical industries who use it, due to some 
specific situation of  the product in manufacture it or a 
in the quality control . Atorvastatin is a lipid-lowering 
medication Patent 1991. The molecular formula is 
C33H34FN2O5, chemical name [R- (R *, R *)] - 2- (4-
fluorophenyl) beta, delta-dihydroxy-5- (1- methylethyl) 
-3-phenyl-4 - [(phenyl-amino) carbonyl] -1-pyrrole-
1heptanoico calcium salt and the Anatomical-
Therapeutic-Chemical (ATC) Classification of the 
World Health Organization identifies with the code: 
 German Madrigal Redondo et al., Sch. Acad. J. Pharm., 2015; 4(2):102-107 
103 
 
C10AA05. The drug is a competitive inhibitor of 
hydroxymethylglutaryl CoA reductase enzyme, 
responsible for the conversion of 3.hidroxi-3-
methylglutaryl coenzyme A to mevalonate, a precursor 
of cholesterol [4, 5, 6]. 
 
 The HMG-CoA reductase inhibitors are 
indicated as an adjunct to diet in the treatment of 
primary hypercholesterolemia (heterozygous familial 
and non-familial) in mixed hyperlipidemia, 
hypercholesterolemia combined with 
hypertriglyceridemia among other diseases with high 
levels of LDL and total cholesterol. Atorvastatin is 
rapidly absorbed after oral administration and the 
maximum concentrations present in 1 to 2 hours post 
administration. It has an absolute bioavailability of 
14%. Has first pass metabolism in the gastric mucosa, 
the volume of distribution is 380 L and joined by about 
98% to plasma proteins[4,7,8]. 
 
MATERIALS AND METHODS 
A qualitative study on a sample of atorvastatin 
was conducted by comparing physicochemical 
parameters reported by the scientific and / or patent 
literature, and those found in the experimentally in the 
laboratory. 
 
Samples of raw material provided by a national 
pharmaceutical industry, which were taken at random 
and taken to the test site under controlled conditions of 
light, temperature and humidity were used. 
 
The results obtained in each of the studies are 
compared with the state of art found in the revised 
bibliography to be able to find similarities and to 
conclude on the crystalline or amorphous state of the 
sample. 
 
There is no official Pharmacopoeia standard 
for comparison so the identification test must be 
conducted using its physicochemical properties by the 
techniques described in the United States of America 
Pharmacopeia 33 and other lscientific literature for 
example Profiles Drugs Substances, and Patents 
[9,10,11,12]. 
 
Tests, equipment and the same conditions used 




Equipment: Diffractometer: Brand Bruker D8 model. 
Conditions: 25 ° C ambient temperature, filter Nickel, 
copper anode source Ka (l 1.54 A °) sample holder 
polymers, continuous analysis to 0.2 ° per second in a 
range of 3 ° to 40 ° 2θ , gas detector photodiodes, 
weight: 8-10 mg sample. Three replicas. 
 
Differential Scanning Calorimetry 
Equipment: brand DSC Q200 TA Instruments model. 
Conditions: Capsule aluminum, 100% nitrogen 
atmosphere 10 psi, flow rate: 40 mL / minute series of 
10 ° C / min, temperature range 25 ° C to 250 ° C, and 
recorder instrument sensitivity: sensitivity 0 1 uW, 
temperature accuracy: ± 0.05 ° C, temperature accuracy 
of ± 0.1 ° C, calorimetric accuracy ± 0.1%, ± 0.1% 




Equipment: TGA Q500 brand TA Instruments model. 
Conditions: 100% nitrogen atmosphere 10 psi, flow 
volume 40 mL / min, heating rate: 10 ° C / minute scan 
0 ° C to 1000 ° C, weight 8-10 mg sample, sensitivity 
0.1 ug , isothermal temperature accuracy of ± 0.1%, 
accuracy ± 0.1% isothermal temperature, mass accuracy 
± 0.01%. Three replicas 
 
 Infrared Spectroscopy 
Equipment: FTIR Brand Thermo Scientific Nicolet 
model 6700 
Conditions: Tablet barium bromide, range 600 to 4000 
cm -1, temperature 25 ° C, relative humidity 30% 
 
RESULTS AND DISCUSSION 
X-ray diffractometry 
The comparison of the XRD pattern shows the 
absence of a crystalline state in the sample analyzed due 
to the absence of characteristic peak. A classical 
diffractogram of a an amorphous structure shows no 
clear peaks with no definite pattern, however, there are 
two areas with a width characterizing bulge 2θ between 
15 and 25 and between 5 and 10 2θ corresponding to 
the amorphous form 27 found in literature. The form 
23, which is also shown in Figure 1, shows a higher 
packing, which is shown with a narrower bulge mainly 
in the second one at 15 to 20 2θ [10,13]. 
 
Figure 2 shows the diffractogram of the 
crystalline form 1 marketed by Pfizer which is totally 
different from the analyzed sample and confirm that the 
raw material is in an amorphous form [13,14]. 
 
The enclosed area in the circle shows the 
typical diffractogram for an amorphous state, where 
there´s no defined peaks, as can be observed in other 
crystalline forms. See Figure 2. 
 
A differential comparison of diffractograms 
found in literature is performed, founding that the 
sample and the artof the amorphous structure forms 27 
are the ones that show greater similarity. These 
diffractograms are not included but can be reviewed in 
the cited literature[10]. 




Fig-1: Comparison of the results shows diffractogram art amorphous forms for Atorvastatin 23 and 27 shown in 
the reference [10]. 
 
 
Fig-2: Polymorphic Form 1 Diffractogram Art marketed by Pfizer Lipitor [10,14]. 
 
Differential Scanning Calorimetry 
Curves a, b, c, d and f, the upper figure shows 
the thermograms of the various samples of the 27 form 
atorvastatin.  Curve e shoes the termograma of form 23. 
The assay sample shows mainly two endotherms; the 
first corresponds to a broad endotherm between 50 and 
100 ° C which coincides with the art, and represents the 
dehydration of the three springs, as shown in TGA 
testing and the second endotherm represents the glass 
transition temperature Tg in an area ranging from 140 
to 160 °C, with an approximate Tg of 154.6 ± 3.0 °C. 
These data alone cannot distinguish between the forms 
23 and 27 as shown in the art, however, using  with 
information obtained from the X-ray diffraction, it can 
be said that 27 form predominates. Is important to note 
that although the aim of this study is to quantify the 
total concentration of each of the amorphous forms 
present in the sample, it can be said that the sample has 
no contamination of crystalline form, but there may be 
some percentage of the amorphous form 23 in 
combination with the form 27, as there is similar pattern 
between the sample thermogram and curve e 
corresponding to form 23, where endotherms are more 
defined due to the higher packing compared to the 27 
form. The sample decomposition begins at 200 ° C as 
shown in the TGA and DSC thermogram [10,13]. 




Fig-3: Comparison of results of DSC of the sample and the art [13]. 
 
Thermogravimetry 
According to structural formula, the water of 
hydration is approximately 4.5% of the total sample 
weight. As seen in art as in the test, the mass loss 
between 40 ° C and 100 °C represents 4.5% of loss, 
corresponding to the three waters of hydration of the 
sample. Also the decomposition of the sample is shown 
from 200 ° C, which coincides with the thermogram of 
Figure 4 (this is shown by the enormous loss of weight, 
about 84.5% in the thermogravitogram). It cannot be 
differentiated with this technique between forms 23 and 
27, however the sum of the assays referred above will 
demonstrate that the predominant form is the form 27 
[10,11,12,13]. 
 
Fig-4: Comparison of results of TGA of the sample with art [13]. 




The characteristic peaks of Atorvastatin can be 
observed in the infrared spectral fingerprint of the 
sample. The similarity of these bands (enclosed in 
circle) is evident. For example the main FTIR peaks are 
due to 1651cm -1 bands corresponding to C = O 
carbonyl group of the amide, the band 2903 cm -1 
corresponds to the aromatic CH group, the band 1595 
cm -1 corresponds to aromatic C = OC, bands 3365 cm -
1 correspond to OH and the band 3228 cm-1 corresponds 
to the NH group. It is also found that the characteristic 
band at 800 cm -1 is specific for crystalline Form 1 of 
atorvastatin and this does not appear in the infrared 
spectrum of the sample indicated by the bold arrows in 
Figure 5. This band is observed in the infrared spectra 
of crystalline form 1. (See figure 6) [10]. 
 
The absence of the peak at 800 cm -1 
characteristic of the crystalline form 1 of calcium 
atorvastatin demonstrates the absence of this crystalline 




Fig-5: Comparison of infrared spectrum of the sample with the art [10]. 
 
Fig-6: Infrared spectrum of crystalline form 1 of calcium atorvastatin [10]. 
 




With this information it can be concluded that: 
The characterization by X-ray diffraction shows the 
existence of the amorphous form 27 of hemi-calcic 
atorvastatin 3H2O. The characterization by X-ray 
diffraction proves that there is nocrystalline 
polymorphic forms contain in the sample.  
 
Assay Differential scanning calorimetry shows 
the existence of two endotherms one between 40 ° C 
and 100 ° C which represents the loss of water, and the 
other between 140 ° C to 160 ° C which corresponds to 
the Tg. Due to the narrowness of the Tg endotherm of 
the sample, there may be a small proportion of the 
sample in form 23, however form 27 is predominant.  
 
Thermogravimetric assay demonstrates the loss 
of mass by 4.5% between 40 ° C and 100 ° C, 
corresponding to the three waters of hydration presents 
the sample. There is a further mass loss after 200 ° C 
corresponds to decomposition of the sample. 
 
Characteristic bands in the infrared showed the 
presence of amorphous atorvastatin form 27. The 
absence of the characteristic peak at 800 cm -1, 
demonstrate the absence of crystalline forms in the 
sample. 
 
In general we can conclude that the trials 
demonstrate the predominant existence of amorphous 
27 form of hemi-calcicatorvastatina 3H2O, and total 
absence of crystalline forms in the sample. 
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